1
|
Wang Y, Song Y, Peng Y, Han S, Qin C, Du Y, Xu T. Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis. Urol Oncol 2024; 42:266-274. [PMID: 38729866 DOI: 10.1016/j.urolonc.2024.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/29/2024] [Accepted: 04/11/2024] [Indexed: 05/12/2024]
Abstract
INTRODUCTION The influence of androgen suppression therapy (AST) on bladder cancer (BCa) remains controversial, as recent studies have not reached a consensus regarding the relationship between AST and the incidence or prognosis of BCa. MATERIALS AND METHODS We perform an updated systematic review and meta-analysis utilizing the most recent evidence to investigate the potential influence of AST on the incidence and prognosis of BCa. A comprehensive literature search was performed on the PubMed, Medline, Embase, Web of Science, and the Cochrane Library databases to include potentially eligible studies. Hazard ratios (HR) and odds ratios (OR) were used to calculate the incidence and prognosis of BCa. RESULTS This meta-analysis included 22 studies with 700,755 participants which investigated the impact of AST on the risk and prognosis of BCa. The pooled results revealed no significant relation between AST and a decreased incidence of BCa (OR: 0.92, 95%CI: 0.77-1.09, P = 0.342). Subgroup analysis reported that patients receiving 5-alpha reductase inhibitors (5-ARIs) exhibited a significantly lower risk of BCa (OR: 0.83, 95%CI: 0.75-0.91, P < 0.001), while androgen deprivation therapy did not show a significant reduction (OR: 1.00, 95%CI: 0.46-2.16, P = 0.995). AST may also significantly improve the recurrence-free survival of patients with BCa (HR: 0.69, 95%CI: 0.50-0.95, P = 0.023). We also detected a significant improvement in OS among BCa patients who received 5-ARIs compared to those without 5-ARIs (HR: 0.82, 95%CI: 0.68-0.99, P = 0.037). CONCLUSION No significant correlation was found between AST and a decreased BCa incidence, while 5-ARIs have demonstrated efficacy in reducing BCa occurrence. Moreover, patients who received AST demonstrated improved prognosis.
Collapse
Affiliation(s)
- Yulong Wang
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China
| | - Yuxuan Song
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China
| | - Yun Peng
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China
| | - Songchen Han
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China
| | - Caipeng Qin
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China
| | - Yiqing Du
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China
| | - Tao Xu
- Department of Urology, Peking University People's Hospital, Beijing 100044, China; The Institute of Applied Lithotripsy Technology, Peking University People's Hospital, Beijing 100044, China.
| |
Collapse
|
2
|
Himura R, Kawano S, Nagata Y, Kawai M, Ota A, Kudo Y, Yoshino Y, Fujimoto N, Miyamoto H, Endo S, Ikari A. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer. Chem Biol Interact 2024; 388:110840. [PMID: 38122923 DOI: 10.1016/j.cbi.2023.110840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 11/27/2023] [Accepted: 12/17/2023] [Indexed: 12/23/2023]
Abstract
Systemic chemotherapy with gemcitabine and cisplatin (GC) has been used for the treatment of bladder cancer in which androgen receptor (AR) signaling is suggested to play a critical role. However, its efficacy is often limited, and the prognosis of patients who develop resistance is extremely poor. Aldo-keto reductase 1C3 (AKR1C3), which is responsible for the production of a potent androgen, 5α-dihydrotestosterone (DHT), by the reduction of 5α-androstane-3α,17β-dione (5α-Adione), has been attracting attention as a therapeutic target for prostate cancer that shows androgen-dependent growth. By contrast, the role of AKR1C3 in bladder cancer remains unclear. In this study, we examined the effect of an AKR1C3 inhibitor on androgen-dependent proliferation and GC sensitivity in bladder cancer cells. 5α-Adione treatment induced the expression of AR and its downstream factor ETS-domain transcription factor (ELK1) in both T24 cells and newly established GC-resistant T24GC cells, while it did not alter AKR1C3 expression. AKR1C3 inhibitor 2j significantly suppressed 5α-Adione-induced AR and ELK1 upregulation, as did an AR antagonist apalutamide. Moreover, the combination of GC and 2j in T24GC significantly induced apoptotic cell death, suggesting that 2j could enhance GC sensitivity. Immunohistochemical staining in surgical specimens further revealed that strong expression of AKR1C3 was associated with significantly higher risks of tumor progression and cancer-specific mortality in patients with muscle-invasive bladder cancer. These results suggest that AKR1C3 inhibitors as adjunctive agents enhance the efficacy of GC therapy for bladder cancer.
Collapse
Affiliation(s)
- Rin Himura
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| | - Shinya Kawano
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| | - Yujiro Nagata
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, 807-8555, Japan
| | - Mina Kawai
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| | - Atsumi Ota
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| | - Yudai Kudo
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| | - Yuta Yoshino
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| | - Naohiro Fujimoto
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, 807-8555, Japan
| | - Hiroshi Miyamoto
- Departments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY, 14642, USA
| | - Satoshi Endo
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan; Center for One Medicine Innovative Translational Research (COMIT), Gifu Pharmaceutical University, Gifu, 501-1193, Japan.
| | - Akira Ikari
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan
| |
Collapse
|
3
|
Zhang Y, Huang Z, Li K, Xie G, Feng Y, Wang Z, Li N, Liu R, Ding Y, Wang J, Yang J, Jia Z. TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression. J Exp Clin Cancer Res 2024; 43:16. [PMID: 38200609 PMCID: PMC10782585 DOI: 10.1186/s13046-023-02920-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 11/30/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND As a novel necrosis manner, ferroptosis has been increasingly reported to play a role in tumor progression and treatment, however, the specific mechanisms underlying its development in prostate cancer remain unclear. Growing evidence showed that peroxisome plays a key role in ferroptosis. Herein, we identified a novel mechanism for the involvement of ferroptosis in prostate cancer progression, which may provide a new strategy for clinical treatment of prostate cancer. METHODS Label-Free Mass spectrometry was used to screen and identify candidate proteins after ferroptosis inducer-ML210 treatment. Immunohistochemistry was undertaken to explore the protein expression of AGPS in prostate cancer tissues compared with normal tissues. Co-immunoprecipitation and GST pull-down were used to identify the directly binding of AGPS to MDM2 in vivo and in vitro. CCK8 assay and colony formation assay were used to illustrate the key role of AGPS in the progression of prostate cancer in vitro. The xenograft model was established to verify the key role of AGPS in the progression of prostate cancer in vivo. RESULTS AGPS protein expression was downregulated in prostate cancer tissues compared with normal tissues from the first affiliated hospital of Zhengzhou University dataset. Lower expression was correlated with poorer overall survival of patients compared to those with high expression of AGPS. In addition, AGPS can promote ferroptosis by modulating the function of peroxisome-resulting in the lower survival of prostate cancer cells. Furthermore, it was shown that AGPS can be ubiquitinated and degraded by the E3 ligase-MDM2 through the proteasomal pathway. Meanwhile, kinase TrkA can promote the combination of AGPS and MDM2 by phosphorylating AGPS at Y451 site. It was verified that kinase TrkA inhibitor-Larotrectinib can increase the susceptibility of prostate cancer cells to ferroptosis, which leads to the inhibition of prostate cancer proliferation to a great extent in vitro and in vivo. CONCLUSION Based on these findings, we proposed the combination of ferroptosis inducer and TrkA inhibitor to synergistically exert anti-tumor effects, which may provide a new strategy for the clinical treatment of prostate cancer.
Collapse
Affiliation(s)
- Yu Zhang
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
- Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905, USA
- Academy of Medical Science, Zhengzhou University, Zhengzhou, 450052, China
| | - Zhenlin Huang
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Keqiang Li
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
- Academy of Medical Science, Zhengzhou University, Zhengzhou, 450052, China
| | - Guoqing Xie
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
- Academy of Medical Science, Zhengzhou University, Zhengzhou, 450052, China
| | - Yuankang Feng
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Zihao Wang
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Ningyang Li
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Ruoyang Liu
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Yinghui Ding
- Department of Otorhinolaryngology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Jun Wang
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
| | - Jinjian Yang
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
| | - Zhankui Jia
- Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
| |
Collapse
|
4
|
Wu S, Ma X, Liang Z, Jiang Y, Chen S, Sun G, Chen K, Liu R. Development and validation of a nomogram for predicting osteoporosis in prostate cancer patients: A cross-sectional study from China. Prostate 2023; 83:1537-1548. [PMID: 37589478 DOI: 10.1002/pros.24612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 07/28/2023] [Accepted: 08/04/2023] [Indexed: 08/18/2023]
Abstract
BACKGROUND The specific risk factors contributing to the development of osteoporosis and the appropriate timing of treatment in Chinese prostate cancer (PCa) patients remain unclear. Our objective was to develop and validate a nomogram capable of predicting the occurrence of osteoporosis in PCa patients. METHODS We conducted a cross-sectional study with PCa patients attending the Second Hospital of Tianjin Medical University, collecting data from June 2021 to February 2023. The patients were divided into training and validation sets in a 7:3 ratio. The LASSO regression was used to identify the most relevant predictive variables, and the multivariable logistic regression was used to construct the nomogram. The nomogram's performance was validated through receiver operating characteristic (ROC) curves, C-index, calibration curves, and decision curve analysis (DCA) in both the training and validation sets. RESULTS We collected data from a total of 596 patients and then constructed the nomogram using age, body mass index, hemoglobin, vitamin D3, testosterone, and androgen deprivation therapy duration. The C-index of the nomogram was 0.923 in the training set and 0.859 in the validation set. The nomogram showed good consistency in both sets. DCA demonstrated the clinical benefit of the nomogram across various prediction thresholds. Furthermore, a separate nomogram was constructed to predict bone loss in patients undergoing ADT, exhibiting equally favorable diagnostic performance and clinical benefit. CONCLUSION This study constructed two reliable nomograms to predict osteoporosis and bone loss, integrating personal health information and PCa-specific treatment data. These nomograms offer an easy and individualized approach to predict the occurrence of osteoporosis and bone loss in PCa patients.
Collapse
Affiliation(s)
- Shangrong Wu
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Xudong Ma
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Zhengxin Liang
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Yuchen Jiang
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Shuaiqi Chen
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Guangyu Sun
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Kaifei Chen
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Ranlu Liu
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| |
Collapse
|
5
|
Tatenuma T, Miyamoto H. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Des Devel Ther 2023; 17:2325-2333. [PMID: 37559910 PMCID: PMC10408655 DOI: 10.2147/dddt.s373546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 08/01/2023] [Indexed: 08/11/2023] Open
Abstract
Androgen deprivation therapy, primarily via a gonadotropin-releasing hormone receptor agonist or antagonist together with or without an androgen receptor antagonist, remains the mainstay of medical treatment for advanced prostate cancer. Meanwhile, relugolix has been developed as the first orally active, non-peptide, selective antagonist for the gonadotropin-releasing hormone receptor. Previous randomized studies involving patients with prostate cancer have demonstrated comparable efficacy in androgen suppression between relugolix vs other gonadotropin-releasing hormone antagonists or agonists. This review summarizes available data on the design and development of relugolix and its therapeutic application, and discusses if relugolix represents a promising oral alternative to injectable androgen deprivation therapy. Based on current published evidence, further investigation is likely required to determine the actual clinical benefits of relugolix therapy against prostate cancer.
Collapse
Affiliation(s)
- Tomoyuki Tatenuma
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiroshi Miyamoto
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA
- Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
| |
Collapse
|
6
|
Yang G, Pan Q, Lu Y, Zhu J, Gou X. miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. Biochem Biophys Res Commun 2023; 652:6-13. [PMID: 36806086 DOI: 10.1016/j.bbrc.2023.02.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 02/10/2023] [Accepted: 02/13/2023] [Indexed: 02/17/2023]
Abstract
Ferroptosis is a kind of regulatory necrosis caused by phospholipid iron-dependent peroxidation. MiRNAs are known to play key roles in diverse biological functions. However, the molecular basis of miRNA-mediated ferroptosis in prostate cancer has not been fully stated. Here, with TCGA prostate cancer miRNA-seq data, we utilized Multivariate Cox regression analysis to prioritize potential miRNA and validated it in vitro and in vivo. We identified miR-29a-5p by TCGA prostate cancer miRNA-seq dataset. And we confirmed the expression of miR-29a-5p in prostate cancer cell lines. MiR-29a-5p knockdown reduced proliferation in PC-3 and LNCaP cells while increased Fe2+ and malondialdehyde (MDA) levels, the opposite phenomenon was observed with miR-29a-5p overexpression. Luciferase reporter assay showed an interaction between miR-29a-5p and Nrf2 downstream gene FTH1, subsequent rescue experiments also indirectly proved their direct effect. Finally, suppression of miR-29a-5p effectively inhibited tumor growth in vivo. These findings proved that the important role of miR-29a-5p in prostate cancer ferroptosis.
Collapse
Affiliation(s)
- Guang Yang
- Department of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
| | - Qi Pan
- Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, PR China
| | - Yang Lu
- Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, PR China
| | - Junlong Zhu
- Department of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
| | - Xin Gou
- Department of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
| |
Collapse
|
7
|
Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study. World J Urol 2022; 40:2459-2466. [PMID: 36057895 PMCID: PMC9512882 DOI: 10.1007/s00345-022-04108-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 07/14/2022] [Indexed: 11/28/2022] Open
Abstract
Purpose Evaluate the percentage of patients with prostate cancer treated with luteinizing hormone-releasing hormone analogues (LHRHa) that develop castration resistance after a follow-up period of 3 years. The secondary objective is to evaluate the variables potentially related to the progression to castration resistant prostate cancer (CRPC). Methods A post-authorization, nation-wide, multicenter, prospective, observational, and longitudinal study that included 416 patients treated with LHRHa between 2012 and 2017 is presented. Patients were followed for 3 years or until development of CRPC, thus completing a per-protocol population of 350 patients. A Cox regression analysis was carried out to evaluate factors involved in progression to CRPC. Results After 3 years of treatment with LHRHa 18.2% of patients developed CRPC. In contrast, in the subgroup analysis, 39.6% of the metastatic patients developed CRPC, compared with 8.8% of the non-metastatic patients. The patients with the highest risk of developing CRPC were those with a nadir prostate-specific antigen (PSA) > 2 ng/ml (HR 21.6; 95% CI 11.7–39.8; p < 0.001) and those receiving concomitant medication, most commonly bicalutamide (HR 1.8; 95% CI 1–3.1, p = 0.0431). Conclusions The proportion of metastatic patients developing CRPC after 3 years of treatment with LHRHa is consistent with what has been previously described in the literature. In addition, this study provides new findings on CRPC in non-metastatic patients. Concomitant medication and nadir PSA are statistically significant predictive factors for the time to diagnosis of CRPC, the nadir PSA being the strongest predictor. Supplementary Information The online version contains supplementary material available at 10.1007/s00345-022-04108-x.
Collapse
|
8
|
McInnis MK, Pukall CF. Sexual script flexibility after a prostate cancer diagnosis: Implications for sexual satisfaction. J Psychosoc Oncol 2022; 41:267-276. [PMID: 36017974 DOI: 10.1080/07347332.2022.2102958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
PURPOSE To investigate the relationship among sexual functioning, sexual script flexibility, and sexual satisfaction in individuals diagnosed with prostate cancer. DESIGN Cross-sectional online survey. PARTICIPANTS Sixty-one men diagnosed with localized prostate cancer. METHODS Online survey of sexual functioning, sexual script flexibility, and sexual satisfaction. Ordinal logistic regression investigated predictors of sexual satisfaction. FINDINGS Greater sexual script flexibility was associated with a greater likelihood of being sexually satisfied. CONCLUSIONS Helping patients explore different ways of being sexual after treatment could help with sexual satisfaction maintenance. IMPLICATIONS Patients' sexual satisfaction may benefit from discussions of issues related to sexuality and ways to work around treatment-related sexual dysfunction with healthcare providers.
Collapse
Affiliation(s)
- Meghan K McInnis
- Department of Psychology, Queen's University, Kingston, ON, Canada
| | | |
Collapse
|
9
|
Sager RA, Backe SJ, Ahanin E, Smith G, Nsouli I, Woodford MR, Bratslavsky G, Bourboulia D, Mollapour M. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nat Rev Urol 2022; 19:305-320. [PMID: 35264774 PMCID: PMC9306014 DOI: 10.1038/s41585-022-00571-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/24/2022] [Indexed: 12/12/2022]
Abstract
The treatment of advanced and metastatic kidney cancer has entered a golden era with the addition of more therapeutic options, improved survival and new targeted therapies. Tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and immune checkpoint blockade have all been shown to be promising strategies in the treatment of renal cell carcinoma (RCC). However, little is known about the best therapeutic approach for individual patients with RCC and how to combat therapeutic resistance. Cancers, including RCC, rely on sustained replicative potential. The cyclin-dependent kinases CDK4 and CDK6 are involved in cell-cycle regulation with additional roles in metabolism, immunogenicity and antitumour immune response. Inhibitors of CDK4 and CDK6 are now commonly used as approved and investigative treatments in breast cancer, as well as several other tumours. Furthermore, CDK4/6 inhibitors have been shown to work synergistically with other kinase inhibitors, including mTOR inhibitors, as well as with immune checkpoint inhibitors in preclinical cancer models. The effect of CDK4/6 inhibitors in kidney cancer is relatively understudied compared with other cancers, but the preclinical studies available are promising. Collectively, growing evidence suggests that targeting CDK4 and CDK6 in kidney cancer, alone and in combination with current therapeutics including mTOR and immune checkpoint inhibitors, might have therapeutic benefit and should be further explored.
Collapse
Affiliation(s)
- Rebecca A Sager
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Sarah J Backe
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Elham Ahanin
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Garrett Smith
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Imad Nsouli
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
- Syracuse VA Medical Center, Syracuse, NY, USA
| | - Mark R Woodford
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Gennady Bratslavsky
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Dimitra Bourboulia
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Mehdi Mollapour
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA.
- Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA.
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA.
- Syracuse VA Medical Center, Syracuse, NY, USA.
| |
Collapse
|
10
|
Celik MA, Erdem H, Cankaya S, Arici YK. Differences in SUV39H1 and androgen receptor distribution in adenomyomatous hyperplasia and prostatic adenocarcinoma. Niger J Clin Pract 2022; 25:1387-1392. [DOI: 10.4103/njcp.njcp_61_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Chen J, Yuan Y, Fang M, Zhu Y, Sun X, Lou Y, Xin Y, Zhou F. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022; 13:1074540. [PMID: 36733800 PMCID: PMC9887024 DOI: 10.3389/fendo.2022.1074540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 12/28/2022] [Indexed: 01/18/2023] Open
Abstract
OBJECTIVES Androgen deprivation therapy combined with radiotherapy for intermediate-risk prostate cancer is still a matter of debate. We conducted a meta-analysis to evaluate the necessity of androgen deprivation therapy combined with radiotherapy for intermediate-risk prostate cancer patients. METHODS A comprehensive literature search of articles was performed in PubMed, Embase, Cochrane library, Web of Science, Chinese National Knowledge Infrastructure, Chinese Biological Medicine, Wanfang, and VIP Databases published between February 1988 and April 2022. Studies comparing the survival of patients diagnosed with intermediate-risk prostate cancer who were treated with androgen deprivation therapy combined with radiotherapy or radiotherapy alone were included. Data were extracted and analyzed with the RevMan software (version 5.3) and the Stata software (version 17). RESULTS Six randomized controlled trials and nine retrospective studies, including 6853 patients (2948 in androgen deprivation therapy combined with radiotherapy group and 3905 in radiotherapy alone group) were enrolled. Androgen deprivation therapy combined with radiotherapy did not provide an overall survival (HR 1.12, 95% CI 1.01-1.12, p=0.04) or biochemical recurrence-free survival (HR 1.23, 95% CI 1.09-1.39, P=0.001) advantage to intermediate-risk prostate cancer patients. CONCLUSION Androgen deprivation therapy combined with radiotherapy did not show some advantages in terms of overall survival and biochemical recurrence-free survival and radiotherapy alone may be the effective therapy for intermediate-risk prostate cancer patients. SYSTEMATIC REVIEW REGISTRATION https://inplasy.com/inplasy-2022-8-0095/, identifier 202280095.
Collapse
Affiliation(s)
- Jiuzhou Chen
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Yan Yuan
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Miao Fang
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Youqi Zhu
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Xueqing Sun
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Yufei Lou
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Yong Xin
- Department of Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- *Correspondence: Yong Xin, ; Fengjuan Zhou,
| | - Fengjuan Zhou
- Department of Radiation, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China
- *Correspondence: Yong Xin, ; Fengjuan Zhou,
| |
Collapse
|
12
|
Comparative pharmacokinetic study of bicalutamide administration alone and in combination with vitamin D in rats. ACTA CHROMATOGR 2021. [DOI: 10.1556/1326.2021.00995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Abstract
Bicalutamide (BCL) has been approved for treatment of advanced prostate cancer (Pca), and vitamin D is inevitably used in combination with BCL in Pca patients for skeletal or anti-tumor strategies. Therefore, it is necessary to study the effect of vitamin D application on the pharmacokinetics of BCL.
We developed and validated a specific, sensitive and rapid UHPLC–MS/MS method to investigate the pharmacokinetic behaviours of BCL in rat plasma with and without the combined use of vitamin D. Plasma samples were extracted by protein precipitation with ether/dichloromethane (2:1 v/v), and the analytes were separated by a Kinetex Biphenyl 100A column (2.1 × 100 mm, 2.6 μm) with a mobile phase composed of 0.5 mM ammonium acetate (PH 6.5) in water (A) and acetonitrile (B) in a ratio of A:B = 35:65 (v/v). Analysis of the ions was run in the multiple reactions monitoring (MRM) mode. The linear range of BCL was 5–2000 ng mL−1. The intra- and inter-day precision were less than 14%, and the accuracy was in the range of 94.4–107.1%. The mean extraction recoveries, matrix effects and stabilities were acceptable for this method. The validated method was successfully applied to evaluate the pharmacokinetic behaviours of BCL in rat plasma. The results demonstrated that the pharmacokinetic property of BCL is significantly affected by combined use of vitamin D, which might help provide useful evidence for the clinical therapy and further pharmacokinetic study.
Collapse
|
13
|
Gu Y, Xue M, Wang Q, Hong X, Wang X, Zhou F, Sun J, Wang G, Peng Y. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis. Int J Mol Sci 2021; 22:ijms222413222. [PMID: 34948018 PMCID: PMC8704202 DOI: 10.3390/ijms222413222] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 11/29/2021] [Accepted: 12/05/2021] [Indexed: 12/12/2022] Open
Abstract
Objective: Prostate cancer (PCa) is the most common malignant tumor diagnosed in men in developed countries. In developing countries, the PCa morbidity and mortality rates are also increasing rapidly. Since androgen receptor (AR) is a key driver and plays a critical role in the regulation of PCa development, AR-targeted agents provide a key component of current therapy regimens. However, even new-generation AR antagonists are prone to drug resistance, and there is currently no effective strategy for overcoming advanced PCa aggressiveness, including drug-resistance progression. The aim of this study was to evaluate the potential efficacy and novel therapy strategy of proxalutamide (a newly developed AR antagonist) in PCa. Methods: Four PCa cell lines with various biological heterogeneities were utilized in this study, namely, androgen-sensitive/-insensitive with/without AR expression. Proliferation, migration and apoptosis assays in PCa cells were used to evaluate the effective therapeutic activity of proxalutamide. The changes in lipid droplet accumulation and lipidomic profiles were analyzed to determine the influence of proxalutamide on lipogenesis in PCa cells. The molecular basis of the effects of proxalutamide on lipogenesis and the AR axis was then further investigated. Results: Proxalutamide significantly inhibited the proliferation and migration of PCa cells, and its inhibitory effect was superior to that of enzalutamide (Enz, second-generation AR antagonist). Proxalutamide induced the caspase-dependent apoptosis of PCa cells. Proxalutamide significantly diminished the level of lipid droplets in PCa cells, changed the lipid profile of PCa cells and reduced the content of most lipids (especially triglycerides) in PCa cells. Proxalutamide attenuated de novo lipogenesis by inhibiting the expression of ATP citrate lyase (ACL), acetyl CoA carboxylase (ACC), fatty acid synthase (FASN) and sterol regulatory element-binding protein-1 (SREBP-1). Moreover, proxalutamide also decreased AR expression in PCa cells, and its inhibitory effect on lipogenesis did not depend on its ability to down-regulate AR expression. However, Enz had no effect on AR expression, lipid accumulation or lipid de novo synthesis in PCa cells. Conclusions: By co-targeting the AR axis and endogenous adipogenesis, a novel and promising strategy was established for proxalutamide to combat the progress of PCa. The unique effect of proxalutamide on the metabolic reprogramming of PCa provides a potential solution to overcome the resistance of current AR-targeted therapy, which will help to effectively prolong its clinical service life.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Ying Peng
- Correspondence: or ; Tel.: +86-25-83271176; Fax: +86-25-83271060
| |
Collapse
|
14
|
Singla RK, Sharma P, Dubey AK, Gundamaraju R, Kumar D, Kumar S, Madaan R, Shri R, Tsagkaris C, Parisi S, Joon S, Singla S, Kamal MA, Shen B. Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies. Front Pharmacol 2021; 12:732266. [PMID: 34737700 PMCID: PMC8560712 DOI: 10.3389/fphar.2021.732266] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 09/06/2021] [Indexed: 02/05/2023] Open
Abstract
Background: With prostate cancer being the fifth-greatest cause of cancer mortality in 2020, there is a dire need to expand the available treatment options. Castration-resistant prostate cancer (CRPC) progresses despite androgen depletion therapy. The mechanisms of resistance are yet to be fully discovered. However, it is hypothesized that androgens depletion enables androgen-independent cells to proliferate and recolonize the tumor. Objectives: Natural bioactive compounds from edible plants and herbal remedies might potentially address this need. This review compiles the available cheminformatics-based studies and the translational studies regarding the use of natural products to manage CRPC. Methods: PubMed and Google Scholar searches for preclinical studies were performed, while ClinicalTrials.gov and PubMed were searched for clinical updates. Studies that were not in English and not available as full text were excluded. The period of literature covered was from 1985 to the present. Results and Conclusion: Our analysis suggested that natural compounds exert beneficial effects due to their broad-spectrum molecular disease-associated targets. In vitro and in vivo studies revealed several bioactive compounds, including rutaecarpine, berberine, curcumin, other flavonoids, pentacyclic triterpenoids, and steroid-based phytochemicals. Molecular modeling tools, including machine and deep learning, have made the analysis more comprehensive. Preclinical and clinical studies on resveratrol, soy isoflavone, lycopene, quercetin, and gossypol have further validated the translational potential of the natural products in the management of prostate cancer.
Collapse
Affiliation(s)
- Rajeev K. Singla
- Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- iGlobal Research and Publishing Foundation, New Delhi, India
| | - Pooja Sharma
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
- Khalsa College of Pharmacy, Amritsar, India
| | | | - Rohit Gundamaraju
- ER Stress and Mucosal Immunology Lab, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, TAS, Australia
| | - Dinesh Kumar
- Department of Pharmaceutical Sciences, Sri Sai College of Pharmacy, Amritsar, India
| | - Suresh Kumar
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| | - Reecha Madaan
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | - Richa Shri
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| | | | - Salvatore Parisi
- Lourdes Matha Institute of Hotel Management and Catering Technology, Thiruvananthapuram, India
| | - Shikha Joon
- Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- iGlobal Research and Publishing Foundation, New Delhi, India
| | - Shailja Singla
- iGlobal Research and Publishing Foundation, New Delhi, India
| | - Mohammad Amjad Kamal
- West China School of Nursing/Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
- Enzymoics; Novel Global Community Educational Foundation, Hebersham, NSW, Australia
| | - Bairong Shen
- Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
15
|
Sun G, Rong D, Li Z, Sun G, Wu F, Li X, Cao H, Cheng Y, Tang W, Sun Y. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Front Cell Dev Biol 2021; 9:694363. [PMID: 34568317 PMCID: PMC8455877 DOI: 10.3389/fcell.2021.694363] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 07/07/2021] [Indexed: 12/13/2022] Open
Abstract
Research on molecular targeted therapy of tumors is booming, and novel targeted therapy drugs are constantly emerging. Small molecule targeted compounds, novel targeted therapy drugs, can be administered orally as tablets among other methods, and do not draw upon genes, causing no immune response. It is easily structurally modified to make it more applicable to clinical needs, and convenient to promote due to low cost. It refers to a hotspot in the research of tumor molecular targeted therapy. In the present study, we review the current Food and Drug Administration (FDA)-approved use of small molecule targeted compounds in tumors, summarize the clinical drug resistance problems and mechanisms facing the use of small molecule targeted compounds, and predict the future directions of the evolving field.
Collapse
Affiliation(s)
- Guoqiang Sun
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Dawei Rong
- Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, China
| | - Zhouxiao Li
- Department of Hand Surgery, Plastic Surgery and Aesthetic Surgery, Ludwig-Maximilians University, Munich, Germany
| | - Guangshun Sun
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Fan Wu
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Xiao Li
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Hongyong Cao
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Ye Cheng
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Weiwei Tang
- Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, China
| | - Yangbai Sun
- Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
| |
Collapse
|
16
|
Fontana F, Limonta P. Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells 2021; 10:1133. [PMID: 34067217 PMCID: PMC8151003 DOI: 10.3390/cells10051133] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 05/05/2021] [Accepted: 05/06/2021] [Indexed: 02/07/2023] Open
Abstract
Understanding the molecular mechanisms underlying prostate cancer (PCa) progression towards its most aggressive, castration-resistant (CRPC) stage is urgently needed to improve the therapeutic options for this almost incurable pathology. Interestingly, CRPC is known to be characterized by a peculiar hormonal landscape. It is now well established that the androgen/androgen receptor (AR) axis is still active in CRPC cells. The persistent activity of this axis in PCa progression has been shown to be related to different mechanisms, such as intratumoral androgen synthesis, AR amplification and mutations, AR mRNA alternative splicing, increased expression/activity of AR-related transcription factors and coregulators. The hypothalamic gonadotropin-releasing hormone (GnRH), by binding to its specific receptors (GnRH-Rs) at the pituitary level, plays a pivotal role in the regulation of the reproductive functions. GnRH and GnRH-R are also expressed in different types of tumors, including PCa. Specifically, it has been demonstrated that, in CRPC cells, the activation of GnRH-Rs is associated with a significant antiproliferative/proapoptotic, antimetastatic and antiangiogenic activity. This antitumor activity is mainly mediated by the GnRH-R-associated Gαi/cAMP signaling pathway. In this review, we dissect the molecular mechanisms underlying the role of the androgen/AR and GnRH/GnRH-R axes in CRPC progression and the possible therapeutic implications.
Collapse
Affiliation(s)
| | - Patrizia Limonta
- Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milano, Italy;
| |
Collapse
|
17
|
Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, Shu F, Tan X, Yang Y, Cen S, Li C, Mao X. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol Res 2021; 164:105305. [PMID: 33197601 DOI: 10.1016/j.phrs.2020.105305] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 10/20/2020] [Accepted: 11/10/2020] [Indexed: 02/07/2023]
Abstract
On account of incurable castration-resistant prostate cancer (CRPC) inevitably developing after treating with androgen deprivation therapy, it is an urgent need to find new therapeutic strategies. Flubendazole is a well-known anti-malarial drug that is recently reported to be a potential anti-tumor agent in various types of human cancer cells. However, whether flubendazole could inhibit the castration-resistant prostate cancer has not been well charified. Thus, the aim of the present study was to characterize the precise mechanism of action of flubendazole on the CRPC. In this study, we investigated the potential effect of flubendazole on cell proliferation, cell cycle and cell death in CRPC cells (PC3 and DU145). We found that flubendazole inhibited cell proliferation, caused cell cycle arrest in G2/M phase and promoted cell death in vitro, and suppressed growth of CRPC tumor in xenograft models. In addition, we reported that flubendazole induced the expression of P53, which partly accounted for the G2/M phase arrest and led to inhibition of the transcription of SLC7A11, and then downregulated the GPX4, which is a major ferroptosis-related gene. Furthermore, flubendazole exhibited synergistic effect with 5-fluorouracil (5-Fu) in chemotherapy of CRPC. This study provides biological evidence that flubendazole is a novel P53 inducer which exerts anti-proliferation and pro-apoptosis effects in CRPC through hindering the cell cycle and activating the ferroptosis, and indicates that a novel utilization of flubendazole in neoadjuvant chemotherapy of CRPC.
Collapse
Affiliation(s)
- Xumin Zhou
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China; Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou 510515, PR China
| | - Libin Zou
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China
| | - Wenbin Chen
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China
| | - Taowei Yang
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China
| | - Junqi Luo
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China
| | - Kaihui Wu
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China
| | - Fangpeng Shu
- Department of Urology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, PR China
| | - Xiao Tan
- Department of Urology, The First Affiliated Hospital, Southwest Medical University, Luzhou 646000, PR China
| | - Yu Yang
- Department of Urology, Peking University Shenzhen Hospital, Shenzhen 518036, PR China
| | - Shengren Cen
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China
| | - Chuanyin Li
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.
| | - Xiangming Mao
- Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.
| |
Collapse
|
18
|
Rahman M, Griffith CC. Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities. Surg Pathol Clin 2021; 14:111-126. [PMID: 33526216 DOI: 10.1016/j.path.2020.09.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with significant mortality. Morphologically, most tumors are characterized by apocrine differentiation with a typical immunophenotype of androgen receptor positive/gross cystic disease fluid protein positive/estrogen receptor negative/progesterone receptor negative. Several morphologic variants of SDC exist, representing diagnostic pitfalls. Several differential diagnoses should be considered because prognosis, treatment, and management may be different from SDC. For SDC, current treatment strategies are aggressive and commonly include surgical excision with lymph node dissection and adjuvant radiotherapy. Continued research is examining the utility of androgen deprivation therapy and targeted molecular therapy.
Collapse
Affiliation(s)
- Mobeen Rahman
- The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic Head and Neck Pathology, Mail Code L25, 9500 Euclid Avenue, Cleveland, OH 44195, USA. https://twitter.com/ENT_path
| | - Christopher C Griffith
- The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic Head and Neck Pathology, Mail Code L25, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
| |
Collapse
|
19
|
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. Cell Death Dis 2020; 11:577. [PMID: 32709853 PMCID: PMC7381652 DOI: 10.1038/s41419-020-02780-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 07/09/2020] [Accepted: 07/10/2020] [Indexed: 12/27/2022]
Abstract
1,2:5,6-Dianhydrogalactitol (DAG) is a bi-functional DNA-targeting agent currently in phase II clinical trial for treatment of temozolomide-resistant glioblastoma (GBM). In the present study, we investigated the cytotoxic activity of DAG alone or in combination with common chemotherapy agents in GBM and prostate cancer (PCa) cells, and determined the impact of DNA repair pathways on DAG-induced cytotoxicity. We found that DAG produced replication-dependent DNA lesions decorated with RPA32, RAD51, and γH2AX foci. DAG-induced cytotoxicity was unaffected by MLH1, MSH2, and DNA-PK expression, but was enhanced by knockdown of BRCA1. Acting in S phase, DAG displayed selective synergy with topoisomerase I (camptothecin and irinotecan) and topoisomerase II (etoposide) poisons in GBM, PCa, and lung cancer cells with no synergy observed for docetaxel. Importantly, DAG combined with irinotecan treatment enhanced tumor responses and prolonged survival of tumor-bearing mice. This work provides mechanistic insight into DAG cytotoxicity in GBM and PCa cells and offers a rational for exploring combination regimens with topoisomerase I/II poisons in future clinical trials.
Collapse
|
20
|
McInnis MK, Pukall CF. Sex After Prostate Cancer in Gay and Bisexual Men: A Review of the Literature. Sex Med Rev 2020; 8:466-472. [DOI: 10.1016/j.sxmr.2020.01.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 01/26/2020] [Accepted: 01/27/2020] [Indexed: 12/24/2022]
|
21
|
Zhou X, Zhang J, Hu X, He P, Guo J, Li J, Lan T, Liu J, Peng L, Li H. Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway. Front Pharmacol 2020; 11:758. [PMID: 32523533 PMCID: PMC7261869 DOI: 10.3389/fphar.2020.00758] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Accepted: 05/06/2020] [Indexed: 12/14/2022] Open
Abstract
Since incurable castration-resistant prostate cancer (CRPC) inevitably develops following treatment with androgen deprivation therapy, there is an urgent need to devise new therapeutic strategies to treat this cancer. Pyrimethamine, an FDA-approved antimalarial drug, is known to exert an antitumor activity in various types of human cancer cells. However, whether pyrimethamine can inhibit prostate cancer is not well established. Hence, the present study aimed to characterize the mechanism of action of pyrimethamine on prostate cancer. We investigated the potential effect of pyrimethamine on cell proliferation, cell cycle, and apoptosis in metastatic DU145 and PC3 prostate cancer cells. We found that pyrimethamine inhibited cell proliferation, induced cell cycle arrest in the S phase, and promoted cell apoptosis of prostate cells in vitro; it also suppressed tumor growth in xenograft models. In addition, we observed that pyrimethamine suppressed prostate cancer growth by inhibiting the p38-NF-κB axis in vitro and in vivo. Thus, this study demonstrates that pyrimethamine is a novel p38 inhibitor that can exert antiproliferative and proapoptotic effects in prostate cancer by affecting cell cycle and intrinsic apoptotic signaling, thereby providing a novel strategy for using pyrimethamine in CRPC treatment.
Collapse
Affiliation(s)
- Xumin Zhou
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China.,Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
| | - Jinming Zhang
- Department of Respiration, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Xiaoping Hu
- Department of Pharmacy, Affiliated Tumor Hospital, Guangzhou Medical University, Guangzhou, China
| | - Peiqing He
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| | - Jianyu Guo
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| | - Jun Li
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| | - Tian Lan
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| | - Jumei Liu
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| | - Lilan Peng
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| | - Hua Li
- Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou, China
| |
Collapse
|
22
|
γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells. Molecules 2020; 25:molecules25020398. [PMID: 31963634 PMCID: PMC7024271 DOI: 10.3390/molecules25020398] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/12/2020] [Accepted: 01/15/2020] [Indexed: 01/22/2023] Open
Abstract
Prostate cancer is the second most commonly diagnosed cancer in men, and metastatic prostate cancer is currently incurable. Prostate cancer frequently becomes resistant to standard of care treatments, and the administration of chemotherapeutic drugs is often accompanied by toxic side effects. Combination therapy is one tool that can be used to combat therapeutic resistance and drug toxicity. Vitamin E (VE) compounds and analogs have been proposed as potential non-toxic chemotherapeutics. Here we modeled combination therapy using mixture design response surface methodology (MDRSM), a statistical technique designed to optimize mixture compositions, to determine whether combinations of three chemotherapeutic agents: γ-tocotrienol (γ-T3), α-tocopherol ether acetate (α-TEA), and docetaxel (DOC), would prove more effective than docetaxel alone in the treatment of human prostate cancer cells. Response surfaces were generated for cell viability, and the optimal treatment combination for reducing cell viability was calculated. We found that a combination of 20 µM γ-T3, 30 µM α-TEA, and 25 nm DOC was most effective in the treatment of PC-3 cells. We also found that the combination of γ-T3 and α-TEA with DOC decreased the amount of DOC required to reduce cell viability in PC-3 cells and ameliorated therapeutic resistance in DOC-resistant PC-3 cells.
Collapse
|
23
|
Anti-androgen hormonal therapy for cancer and other diseases. Eur J Pharmacol 2020; 866:172783. [DOI: 10.1016/j.ejphar.2019.172783] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 10/29/2019] [Accepted: 11/07/2019] [Indexed: 01/27/2023]
|
24
|
Xu S, Wu X, Tao Z, Li H, Fan C, Chen S, Guo J, Ning Y, Hu X. Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells. Genes Genomics 2019; 42:299-307. [PMID: 31872382 DOI: 10.1007/s13258-019-00903-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Accepted: 12/04/2019] [Indexed: 02/01/2023]
Abstract
BACKGROUND Androgen-independent prostate cancer (AIPC) is an extremely malignant tumor developed from the androgen dependent (ADPC). However, the mechanism of transition process from ADPC to AIPC remains unknown. OBJECTIVE Here we aimed to identify the androgen receptor (AR) target gene and its roles in AIPC. METHODS Target genes of AR were identified by ChIP-seq in AIPC cells. AR target gene PCDH7 was detected by real time PCR and western blot. Methylation of PCDH7 was measured by bisulfite sequencing and bisulfite amplicon sequencing. Cell growth, invasion and apoptosis were measured by CCK-8, transwell and flow cytometry, respectively. RESULTS AR was significantly enriched in the upstream of PCDH7 gene. The expression of PCDH7 was significantly decreased, while the methylation of PCDH7 was increased in the AIPC cells compared to the ADPC cells. DNA methyltransferase inhibitor significantly suppressed the methylation and increased the mRNA and protein level of PCDH7. Moreover, overexpression of DNMT1 remarkably reduced the mRNA and protein level of PCDH7. DNA methyltransferase inhibitor decreased the cell growth and invasion while promote the cell apoptosis in the AIPC cells. AR significantly target PCDH7, whose hypermethylation may repress cell growth and invasion, and promote apoptosis in AIPC. CONCLUSIONS This study might provide a novel potential target for the treatment of AIPC.
Collapse
Affiliation(s)
- Siqi Xu
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Xiaoyan Wu
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Zhihua Tao
- The Clinical Laboratory of the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China
| | - Hongsheng Li
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Chenliang Fan
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Songjin Chen
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Jianwei Guo
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Yao Ning
- The Clinical Laboratory of the Second Hospital of Jiaxing, Jiaxing, 314000, China
| | - Xuqi Hu
- The Orthopaedics Department of the Second Hospital of Jiaxing, No. 1518, Huancheng North Road, Nanhu District, Jiaxing, 314000, Zhejiang, China.
| |
Collapse
|
25
|
Nagata Y, Goto T, Miyamoto H. The Role of Mineralocorticoid Receptor Signaling in Genitourinary Cancers. NUCLEAR RECEPTOR RESEARCH 2019. [DOI: 10.32527/2019/101410] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Yujiro Nagata
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
- Department of Urology, University of Occupational and Environmental Health School of Medicine, Kitakyushu, Fukuoka 807-8555, Japan
| | - Takuro Goto
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Hiroshi Miyamoto
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
- Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
| |
Collapse
|
26
|
Johnson BM, Radwan FFY, Hossain A, Doonan BP, Hathaway-Schrader JD, God JM, Voelkel-Johnson CV, Banik NL, Reddy SV, Haque A. Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. J Cell Biochem 2018; 120:6264-6276. [PMID: 30378157 DOI: 10.1002/jcb.27913] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Accepted: 09/25/2018] [Indexed: 12/11/2022]
Abstract
Though the current therapies are effective at clearing an early stage prostate cancer, they often fail to treat late-stage metastatic disease. We aimed to investigate the molecular mechanisms underlying the anticancer effects of a natural triterpenoid, ganoderic acid DM (GA-DM), on two human prostate cancer cell lines: the androgen-independent prostate carcinoma (PC-3), and androgen-sensitive prostate adenocarcinoma (LNCaP). Cell viability assay showed that GA-DM was relatively more toxic to LNCaP cells than to PC-3 cells (IC50 s ranged 45-55 µM for PC-3, and 20-25 µM for LNCaP), which may have occurred due to differential expression of p53. Hoechst DNA staining confirmed detectable nuclear fragmentation in both cell lines irrespective of the p53 status. GA-DM treatment decreased Bcl-2 proteins while it upregulated apoptotic Bax and autophagic Beclin-1, Atg5, and LC-3 molecules, and caused an induction of both early and late events of apoptotic cell death. Biochemical analyses of GA-DM-treated prostate cancer cells demonstrated that caspase-3 cleavage was notable in GA-DM-treated PC-3 cells. Interestingly, GA-DM treatment altered cell cycle progression in the S phase with a significant growth arrest in the G2 checkpoint and enhanced CD4 + T cell recognition of prostate tumor cells. Mechanistic study of GA-DM-treated prostate cancer cells further demonstrated that calpain activation and endoplasmic reticulum stress contributed to cell death. These findings suggest that GA-DM is a candidate for future drug design for prostate cancer as it activates multiple pathways of cell death and immune recognition.
Collapse
Affiliation(s)
- Benjamin M Johnson
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.,Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Faisal F Y Radwan
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.,Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Azim Hossain
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.,Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Bently P Doonan
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.,Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Jessica D Hathaway-Schrader
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina
| | - Jason M God
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.,Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Christina V Voelkel-Johnson
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina
| | - Narendra L Banik
- Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina
| | - Sakamuri V Reddy
- Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Azizul Haque
- Department of Microbiology and Immunology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.,Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| |
Collapse
|
27
|
Shinder BM, Shupe A, Lee GT, Stein MN, Kim IY, Singer EA. Role of the androgen signaling axis in genitourinary malignancies. Transl Cancer Res 2018; 7:1135-1142. [PMID: 30701159 DOI: 10.21037/tcr.2018.03.41] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
As we learn more about the molecular biology of genitourinary malignancies, novel therapeutic strategies can be developed. This is especially crucial for prostate, renal, and bladder cancer, where mortality rates remain high especially in advanced disease states. The androgen signaling axis and the androgen receptor (AR) are areas that are actively being explored for their role in these diseases. Although long been associated with prostate cancer development and progression, the role of AR in renal cell carcinoma (RCC) and bladder cancer is becoming recognized as well. This review will highlight the current research into the role of the androgen signaling axis in genitourinary malignancies and how this pathway is being used to expand our therapeutic armamentarium.
Collapse
Affiliation(s)
- Brian M Shinder
- Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Adam Shupe
- Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Geun Taek Lee
- Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Mark N Stein
- Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Isaac Y Kim
- Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Eric A Singer
- Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| |
Collapse
|
28
|
Ide H, Inoue S, Mizushima T, Jiang G, Chuang KH, Oya M, Miyamoto H. Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer. Mol Cancer Ther 2018; 17:1566-1574. [PMID: 29720561 DOI: 10.1158/1535-7163.mct-17-1061] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Revised: 12/28/2017] [Accepted: 04/27/2018] [Indexed: 11/16/2022]
Abstract
Although radiotherapy often with chemotherapy has been shown to offer a survival benefit comparable with that of radical cystectomy in select patients with bladder cancer, the development of radiosensitization strategies may significantly enhance its application. Notably, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression. We here assessed whether AR signals could contribute to modulating radiosensitivity in bladder cancer cells. Ionizing radiation reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of AR-positive lines. Similarly, in AR-positive cells cultured in androgen-depleted conditions, dihydrotestosterone treatment lowered the effects of irradiation. Meanwhile, an antiandrogen hydroxyflutamide enhanced them in AR-positive cells cultured in the presence of androgens. AR knockdown or hydroxyflutamide treatment also resulted in a delay in DNA double-strand break repair 4-24 hours after irradiation. We then established "radiation-resistant" sublines and found considerable elevation of the expression of AR as well as DNA repair genes, such as ATR, CHEK1, and PARP-1, in these sublines, compared with respective controls. Furthermore, dihydrotestosterone induced the expression of these DNA repair genes in irradiated AR-positive cells, and hydroxyflutamide antagonized the androgen effects. Finally, in a mouse xenograft model, low-dose flutamide was found to enhance the inhibitory effects of irradiation, and its tumor size was similar to that of AR knockdown line with radiation alone. These findings suggest that AR activity inversely correlates with radiosensitivity in bladder cancer. Accordingly, antiandrogenic drugs may function as sensitizers of irradiation, especially in patients with AR-positive urothelial cancer. Mol Cancer Ther; 17(7); 1566-74. ©2018 AACR.
Collapse
Affiliation(s)
- Hiroki Ide
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Urology, Keio University School of Medicine, Tokyo, Japan
| | - Satoshi Inoue
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York
| | - Taichi Mizushima
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York
| | - Guiyang Jiang
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York
| | - Kuang-Hsiang Chuang
- Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York
| | - Mototsugu Oya
- Department of Urology, Keio University School of Medicine, Tokyo, Japan
| | - Hiroshi Miyamoto
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. .,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.,Department of Urology, University of Rochester Medical Center, Rochester, New York
| |
Collapse
|
29
|
Inoue S, Mizushima T, Miyamoto H. Role of the androgen receptor in urothelial cancer. Mol Cell Endocrinol 2018; 465:73-81. [PMID: 28652170 DOI: 10.1016/j.mce.2017.06.021] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Revised: 06/19/2017] [Accepted: 06/21/2017] [Indexed: 12/22/2022]
Abstract
Men have had a substantially higher risk of developing bladder cancer than women. This has prompted research on androgen-mediated androgen receptor (AR) signaling in urothelial cancer. Indeed, increasing preclinical evidence indicates that AR activation correlates with the promotion of urothelial carcinogenesis and tumor outgrowth. In this article, we summarize and discuss available data suggesting the involvement of androgens and the AR pathway in the development and progression of urothelial cancer. Although precise mechanisms for the functions of AR and related signals in urothelial cells remain far from being fully understood, current observations may offer effective chemopreventive and therapeutic approaches for urothelial cancer. Clinical application of various anti-AR therapies available for AR-dependent prostate cancer to urothelial cancer patients is thus anticipated.
Collapse
Affiliation(s)
- Satoshi Inoue
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
| | - Taichi Mizushima
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
| | - Hiroshi Miyamoto
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; Department of Urology, University of Rochester Medical Center, Rochester, NY, USA.
| |
Collapse
|
30
|
Cozar J, Robles-Fernandez I, Martinez-Gonzalez L, Pascual-Geler M, Rodriguez-Martinez A, Serrano M, Lorente J, Alvarez-Cubero M. Genetic markers a landscape in prostate cancer. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH 2018; 775:1-10. [DOI: 10.1016/j.mrrev.2017.11.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 11/21/2017] [Accepted: 11/28/2017] [Indexed: 12/19/2022]
|
31
|
Polotti CF, Kim CJ, Chuchvara N, Polotti AB, Singer EA, Elsamra S. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics. Expert Opin Drug Metab Toxicol 2017; 13:1265-1273. [PMID: 29137489 DOI: 10.1080/17425255.2017.1405934] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Medical therapy has undergone many changes as our understanding of prostate cancer cell biology has improved. Androgen deprivation therapy (ADT) remains the mainstay of therapy for metastatic disease. Metastatic castrate-resistant prostate cancer (CRPC) is an important concern since we are unable to stop progression with currently available agents. Areas covered: Pharmacologic ADT is the most commonly used treatment for metastatic prostate cancer. Multiple agents are available for both first-line and second-line use: antiandrogens, estrogens, luteinizing hormone-releasing hormone agonists/antagonists, and CYP17 inhibitors. With adoption of these drugs, it is important to consider their pharmacokinetic and pharmacodynamic properties. Many undergo metabolism through cytochrome P450. Levels may be altered with co-administration of drugs acting as enzyme inhibitors or inducers. Understanding mechanism of action, metabolism, and excretion of these drugs allows clinicians to provide the best therapeutic care while minimizing adverse events. Expert opinion: Many men with metastatic prostate cancer will progress to castration resistance. An understanding of resistance mechanisms at the cellular level has revealed new drug targets with hopes of halting or reversing progression of metastatic disease. Second-line agents, traditionally reserved for CRPC, are being studied in metastatic castrate-sensitive prostate cancer, and may offer practice-changing evidence supporting their use.
Collapse
Affiliation(s)
- Charles F Polotti
- a Division of Urology , Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA
| | - Christopher J Kim
- a Division of Urology , Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA
| | - Nadiya Chuchvara
- a Division of Urology , Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA
| | - Alyssa B Polotti
- b Department of Pharmacy Practice and Pharmacy Administration , University of the Sciences, Philadelphia College of Pharmacy , Philadelphia , PA , USA
| | - Eric A Singer
- c Section of Urologic Oncology , Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA
| | - Sammy Elsamra
- a Division of Urology , Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA.,c Section of Urologic Oncology , Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA
| |
Collapse
|
32
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and (select 5863 from (select(sleep(5)))nccq)-- llmm] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
33
|
Poon Y, Pechlivanoglou P, Alibhai SMH, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017; 121:17-28. [PMID: 28921820 DOI: 10.1111/bju.14015] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Androgen-deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This review compared the efficacy of available treatments to provide prescribing guidance to healthcare professionals. This is the first review to compare the effectiveness of different osteoporotic treatments (bisphosphonates, denosumab, toremifene, and raloxifene) on BMD in patients with non-metastatic prostate cancer on ADT using network meta-analysis. Results suggest that all evaluated treatments are effective in improving BMD compared to placebo. Zoledronic acid (ZA) was found to have a greater improvement in BMD compared to other active treatments at all three studied sites, except for risedronate, which had better BMD improvement compared to ZA at the femoral neck site in one small study. Our study did not identify evidence that one drug is unequivocally more effective than another. All drugs appeared to be effective in reducing the rate of bone loss. Healthcare professionals should also consider patient preference, costs, and local availability as part of the decision process.
Collapse
Affiliation(s)
- Yeesha Poon
- The University of Toronto, Toronto, ON, Canada
| | - Petros Pechlivanoglou
- The University of Toronto, Toronto, ON, Canada.,Toronto Health Economic and Technology Assessment Collaborative, Toronto, ON, Canada.,The Hospital for Sick Children, Toronto, ON, Canada.,Institute of Health Policy Management and Evaluation, Toronto, ON, Canada
| | - Shabbir M H Alibhai
- The University of Toronto, Toronto, ON, Canada.,Toronto Health Economic and Technology Assessment Collaborative, Toronto, ON, Canada.,Institute of Health Policy Management and Evaluation, Toronto, ON, Canada.,University Health Network, Toronto, ON, Canada
| | - David Naimark
- The University of Toronto, Toronto, ON, Canada.,Institute of Health Policy Management and Evaluation, Toronto, ON, Canada.,Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Jeffrey S Hoch
- The University of Toronto, Toronto, ON, Canada.,Institute of Health Policy Management and Evaluation, Toronto, ON, Canada.,Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.,Department of Public Health Sciences, University of California, Davis, Sacramento, CA, USA
| | | | | | - Murray Krahn
- The University of Toronto, Toronto, ON, Canada.,Toronto Health Economic and Technology Assessment Collaborative, Toronto, ON, Canada.,Institute of Health Policy Management and Evaluation, Toronto, ON, Canada.,University Health Network, Toronto, ON, Canada
| |
Collapse
|
34
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null,null,null-- muqg] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
35
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null-- hets] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
36
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 order by 2320-- qdof] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
37
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and 7021=dbms_pipe.receive_message(chr(105)||chr(104)||chr(107)||chr(119),5)-- tlyd] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
38
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null,null,null,null,null,null,null,null,null-- fzos] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
39
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null,null,null,null,null-- qhvx] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
40
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and 7021=dbms_pipe.receive_message(chr(105)||chr(104)||chr(107)||chr(119),5)] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
41
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null,null,null,null,null,null-- qixb] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
42
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null,null,null,null,null,null,null-- oqme] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
43
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and (select 5863 from (select(sleep(5)))nccq)] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
44
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null-- myvn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
45
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and 2121=6958-- ytdc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
46
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and 7386=(select 7386 from pg_sleep(5))] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
47
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 and 9855=cast((chr(113)||chr(98)||chr(112)||chr(118)||chr(113))||(select (case when (9855=9855) then 1 else 0 end))::text||(chr(113)||chr(122)||chr(98)||chr(98)||chr(113)) as numeric)-- zmhj] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
48
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 union all select null,null,null,null,null,null,null,null,null-- kkui] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
49
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 waitfor delay '0:0:5'-- mani] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|
50
|
Poon Y, Pechlivanoglou P, Alibhai SM, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2017. [DOI: 10.1111/bju.14015 waitfor delay '0:0:5'] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Yeesha Poon
- The University of Toronto; Toronto ON Canada
| | - Petros Pechlivanoglou
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- The Hospital for Sick Children; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
| | - Shabbir M.H. Alibhai
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| | - David Naimark
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - Jeffrey S. Hoch
- The University of Toronto; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- Li Ka Shing Knowledge Institute of St. Michael's Hospital; Toronto ON Canada
- Department of Public Health Sciences; University of California, Davis; Sacramento CA USA
| | | | | | - Murray Krahn
- The University of Toronto; Toronto ON Canada
- Toronto Health Economic and Technology Assessment Collaborative; Toronto ON Canada
- Institute of Health Policy Management and Evaluation; Toronto ON Canada
- University Health Network; Toronto ON Canada
| |
Collapse
|